|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108.
2005.
|
|
2
|
Travis WD, Brambilla E, Noguchi M, et al:
International Association for the Study of Lung Cancer/American
Thoracic Society/European Respiratory Society international
multidisciplinary classification of lung adenocarcinoma. J Thorac
Oncol. 6:244–285. 2011.
|
|
3
|
Fukuoka M, Yano S, Giaccone G, et al:
Multi-institutional randomized phase II trial of gefitinib for
previously treated patients with advanced non-small-cell lung
cancer (The IDEAL 1 Trial). J Clin Oncol. 21:2237–2246. 2003.
|
|
4
|
Pao W, Miller V, Zakowski M, et al: EGF
receptor gene mutations are common in lung cancers from ‘never
smokers’ and are associated with sensitivity of tumors to gefitinib
and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004.
|
|
5
|
Azzoli CG, Baker S Jr, Temin S, et al:
American Society of Clinical Oncology: American Society of Clinical
Oncology clinical practice guideline update on chemotherapy for
stage IV non-small-cell lung cancer. J Clin Oncol. 27:6251–6266.
2009.
|
|
6
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004.
|
|
7
|
Soda M, Choi YL, Enomoto M, et al:
Identification of the transforming EML4-ALK fusion gene in
non-small-cell lung cancer. Nature. 448:561–566. 2007.
|
|
8
|
Rodig SJ, Mino-Kenudson M, Dacic S, et al:
Unique clinicopathologic features characterize ALK-rearranged lung
adenocarcinoma in the western population. Clin Cancer Res.
15:5216–5223. 2009.
|
|
9
|
Shaw AT, Yeap BY, Mino-Kenudson M, et al:
Clinical features and outcome of patients with non-small-cell lung
cancer who harbor EML4-ALK. J Clin Oncol. 27:4247–4253. 2009.
|
|
10
|
Kwak EL, Bang YJ, Camidge DR, et al:
Anaplastic lymphoma kinase inhibition in non-small-cell lung
cancer. N Engl J Med. 363:1693–1703. 2010.
|
|
11
|
Takahashi T, Sonobe M, Kobayashi M, et al:
Clinicopathologic features of non-small-cell lung cancer with
EML4-ALK fusion gene. Ann Surg Oncol. 17:889–897. 2010.
|
|
12
|
Yoshida A, Tsuta K, Nakamura H, et al:
Comprehensive histologic analysis of ALK-rearranged lung
carcinomas. Am J Surg Pathol. 35:1226–1234. 2011.
|
|
13
|
Wong DW, Leung EL, So KK, et al:
University of Hong Kong Lung Cancer Study Group: The EML4-ALK
fusion gene is involved in various histologic types of lung cancers
from nonsmokers with wild-type EGFR and KRAS. Cancer.
115:1723–1733. 2009.
|
|
14
|
Christensen JG, Zou HY, Arango ME, et al:
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor
of anaplastic lymphoma kinase and c-Met, in experimental models of
anaplastic large-cell lymphoma. Mol Cancer Ther. 6:3314–3322.
2007.
|
|
15
|
Takeuchi K, Choi YL, Togashi Y, et al:
KIF5B-ALK, a novel fusion oncokinase identified by an
immunohistochemistry-based diagnostic system for ALK-positive lung
cancer. Clin Cancer Res. 15:3143–3149. 2009.
|
|
16
|
Yi ES, Boland JM, Maleszewski JJ, et al:
Correlation of IHC and FISH for ALK gene rearrangement in non-small
cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol.
6:459–465. 2011.
|
|
17
|
FDA. FDA summary of safety and
effectiveness data. http://www.accessdata.fda.gov/cdrh_docs/pdf11/p110012b.pdf.
Accessed August 26, 2011
|
|
18
|
Baselga E, Torrelo A, Drolet BA, Zambrano
A, Alomar A and Esterly NB: Familial nonmembranous aplasia cutis of
the scalp. Pediatr Dermatol. 22:213–217. 2005.
|
|
19
|
Elkin EB, Weinstein MC, Winer EP, Kuntz
KM, Schnitt SJ and Weeks JC: HER-2 testing and trastuzumab therapy
for metastatic breast cancer: a cost-effectiveness analysis. J Clin
Oncol. 22:854–863. 2004.
|
|
20
|
Gouvêa AP, Milanezi F, Olson SJ, Leitao D,
Schmitt FC and Gobbi H: Selecting antibodies to detect HER2
overexpression by immunohistochemistry in invasive mammary
carcinomas. Appl Immunohistochem Mol Morphol. 14:103–108. 2006.
|
|
21
|
Roche PC, Suman VJ, Jenkins RB, et al:
Concordance between local and central laboratory HER2 testing in
the breast intergroup trial N9831. J Natl Cancer Inst. 94:855–857.
2002.
|
|
22
|
Vance GH, Barry TS, Bloom KJ, et al:
College of American Pathologists: Genetic heterogeneity in HER2
testing in breast cancer: panel summary and guidelines. Arch Pathol
Lab Med. 133:611–612. 2009.
|
|
23
|
Allred DC and Swanson PE: Testing for
erbB-2 by immunohistochemistry in breast cancer. Am J Clin Pathol.
113:171–175. 2000.
|
|
24
|
Conklin CM, Craddock KJ, Have C, Laskin J,
Couture C and Ionescu DN: Immunohistochemistry is a reliable
screening tool for identification of ALK rearrangement in
non-small-cell lung carcinoma and is antibody dependent. J Thorac
Oncol. 8:45–51. 2013.
|
|
25
|
Mino-Kenudson M, Chirieac LR, Law K, et
al: A novel, highly sensitive antibody allows for the routine
detection of ALK-rearranged lung adenocarcinomas by standard
immunohistochemistry. Clin Cancer Res. 16:1561–1571. 2010.
|
|
26
|
Park HS, Lee JK, Kim DW, et al:
Immunohistochemical screening for anaplastic lymphoma kinase (ALK)
rearrangement in advanced non-small cell lung cancer patients. Lung
Cancer. 77:288–292. 2012.
|
|
27
|
Li Y, Pan Y, Wang R, et al: ALK-rearranged
lung cancer in Chinese: a comprehensive assessment of
clinicopathology, IHC, FISH and RT-PCR. PLoS One. 8:e690162013.
|
|
28
|
Kawahara A, Akiba J, Abe H, et al:
Eml4-alk-positive lung adenocarcinoma with signet-ring cells. Diagn
Cytopathol. 42:460–463. 2014.
|
|
29
|
Takamochi K, Takeuchi K, Hayashi T, Oh S
and Suzuki K: A rational diagnostic algorithm for the
identification of ALK rearrangement in lung cancer: a comprehensive
study of surgically treated Japanese patients. PLoS One.
8:e697942013.
|
|
30
|
Selinger CI, Rogers TM, Russell PA, et al:
Testing for ALK rearrangement in lung adenocarcinoma: a multicenter
comparison of immunohistochemistry and fluorescent in situ
hybridization. Mod Pathol. 26:1545–1553. 2013.
|
|
31
|
Lindeman NI, Cagle PT, Beasley MB, et al:
Molecular testing guideline for selection of lung cancer patients
for EGFR and ALK tyrosine kinase inhibitors: guideline from the
College of American Pathologists, International Association for the
Study of Lung Cancer, and Association for Molecular Pathology. Arch
Pathol Lab Med. 137:828–860. 2013.
|
